Moleculin Historical Valuation

MBRX
 Stock
  

USD 1.50  0.05  3.45%   

Some fundamental drivers such as market cap or Moleculin Biotech enterprice value can be analyzed from historical perspective to project value of the company into the future. Some investors analyze Moleculin Biotech valuation indicators such as Tangible Asset Value of 78.7 M or Working Capital of 74.3 M to time the market or to short-sell their positions based on the trend in valuation ratios. It is a perfect tool to project the direction of Moleculin Biotech's future value. Financial Statement Analysis is much more than just reviewing and breaking down Moleculin Biotech prevalent accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Moleculin Biotech is a good buy for the upcoming year.
Additionally, see Stocks Correlation.
  
Refresh
Share

About Moleculin Valuation Data Analysis

Valuation is the financial process of determining what Moleculin Biotech is worth. Moleculin Biotech valuation ratios put that insight into the context of a company's share price, where they serve as useful tools for evaluating and utilizing investment potential. Moleculin Biotech valuation ratios help investors to determine whether Moleculin Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Moleculin with respect to the benefits of owning Moleculin Biotech security.

Moleculin Biotech Valuation Data Chart

Moleculin valuation ratios help to determine how cheap or expensive it is, compared to its peers or based on some benchmark measure of value for a given date. A typical valuation ratio shows the difference between the cost of Moleculin equity instrument and the benefits of owning shares of Moleculin Biotech CS.
Moleculin Biotech Average Assets are fairly stable at the moment as compared to the past year. Moleculin Biotech reported Average Assets of 91.53 Million in 2021. Average Equity is likely to rise to about 89.9 M in 2022, whereas Net Income Per Employee is likely to drop (1 M) in 2022.

Average Assets

Average asset value for the period used in calculation of Return on Average Equity and Return on Average Assets; derived from Total Assets.

Enterprise Value

Enterprise Value (or EV) is usually referred to as Moleculin Biotech theoretical takeover price. In the event of an acquisition, an acquirer would have to take on Moleculin Biotech debt, but would also pocket its cash. Enterprise Value is more accurate representation of Moleculin Biotech value than its market capitalization because it takes into account all of Moleculin Biotech CS existing debt. Enterprise value is a measure of the value of a business as a whole; calculated as Market Capitalization plus Total Debt USD minus Cash and Equivalents USD.

Market Capitalization

Market capitalization (or market cap) is the total value of the shares outstanding of Moleculin Biotech CS. It is equal to Moleculin Biotech current share price times the number of Moleculin Biotech outstanding shares. Represents the product of [SharesBas]; [Price] and [ShareFactor].
Most indicators from Moleculin Biotech valuation accounts are interrelated and interconnected. However, analyzing valuation accounts indicators one by one will only give a small insight into Moleculin Biotech current financial condition. On the other hand, looking into the entire matrix of valuation accounts indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Additionally, see Stocks Correlation.Moleculin Biotech Average Assets are fairly stable at the moment as compared to the past year. Moleculin Biotech reported Average Assets of 91.53 Million in 2021. Average Equity is likely to rise to about 89.9 M in 2022, whereas Net Income Per Employee is likely to drop (1 M) in 2022.
 2019 2020 2021 2022 (projected)
Tangible Asset Value14.09 M17.88 M72.94 M78.7 M
Market Capitalization41.85 M49.79 M53.15 M51.11 M

Moleculin Biotech valuation accounts Correlations

Moleculin Biotech Account Relationship Matchups

Moleculin Biotech valuation accounts Accounts

201720182019202020212022 (projected)
Net Income Per Employee(1.23 M)(913.54 K)(825.31 K)(1.15 M)(934.94 K)(1.01 M)
Average Assets20.42 M22.37 M27.2 M28.26 M91.53 M98.75 M
Earnings Before Interest Taxes and Depreciation Amortization EBITDA(9.79 M)(11.81 M)(13.23 M)(17.16 M)(15.73 M)(16.14 M)
Earnings Before Interest Taxes and Depreciation Amortization USD(9.79 M)(11.81 M)(13.23 M)(17.16 M)(15.73 M)(16.14 M)
Earnings before Tax(9.8 M)(11.88 M)(13.43 M)(17.36 M)(15.89 M)(16.31 M)
Average Equity17.8 M16.64 M17.83 M15.79 M83.37 M89.95 M
Enterprise Value30.58 M19.61 M26.74 M37.19 M(21.95 M)(22.53 M)
Free Cash Flow(7.35 M)(12.62 M)(17.25 M)(18.14 M)(18.97 M)(19.47 M)
Invested Capital(1.59 M)(2.58 M)58 K(51 K)(1.52 M)(1.56 M)
Invested Capital Average(1.37 M)(2.15 M)(4.8 M)(107.75 K)(1.3 M)(1.41 M)
Market Capitalization39.31 M28.21 M41.85 M49.79 M53.15 M51.11 M
Tangible Asset Value8.34 M8.44 M14.09 M17.88 M72.94 M78.7 M
Working Capital6.09 M4.1 M9.91 M14.28 M68.88 M74.31 M

Moleculin Biotech Investors Sentiment

The influence of Moleculin Biotech's investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Moleculin. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock markets does not have a solid backing from leading economists and market statisticians.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Moleculin Biotech in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Moleculin Biotech's short interest history, or implied volatility extrapolated from Moleculin Biotech options trading.

Current Sentiment - MBRX

Moleculin Biotech Investor Sentiment

Most of Macroaxis users are now bullish on Moleculin Biotech CS. What is your trading attitude regarding investing in Moleculin Biotech CS? Are you bullish or bearish?
Bullish
Bearish
98% Bullish
2% Bearish

Becoming a Better Investor with Macroaxis

Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Moleculin Biotech using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Additionally, see Stocks Correlation. Note that the Moleculin Biotech information on this page should be used as a complementary analysis to other Moleculin Biotech's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Aroon Oscillator module to analyze current equity momentum using Aroon Oscillator and other momentum ratios.

Complementary Tools for Moleculin Stock analysis

When running Moleculin Biotech price analysis, check to measure Moleculin Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Moleculin Biotech is operating at the current time. Most of Moleculin Biotech's value examination focuses on studying past and present price action to predict the probability of Moleculin Biotech's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Moleculin Biotech's price. Additionally, you may evaluate how the addition of Moleculin Biotech to your portfolios can decrease your overall portfolio volatility.
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Go
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Go
Focused Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Go
Money Managers
Screen money managers from public funds and ETFs managed around the world
Go
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Go
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Go
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Go
Probability Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Go
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Go
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Go
Is Moleculin Biotech's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Moleculin Biotech. If investors know Moleculin will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Moleculin Biotech listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
42.9 M
Return On Assets
-0.17
Return On Equity
-0.23
The market value of Moleculin Biotech is measured differently than its book value, which is the value of Moleculin that is recorded on the company's balance sheet. Investors also form their own opinion of Moleculin Biotech's value that differs from its market value or its book value, called intrinsic value, which is Moleculin Biotech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Moleculin Biotech's market value can be influenced by many factors that don't directly affect Moleculin Biotech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Moleculin Biotech's value and its price as these two are different measures arrived at by different means. Investors typically determine Moleculin Biotech value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Moleculin Biotech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.